| Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. | |
| | |
MedLine Citation:
|
PMID: 21929536 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: There are limited data on the use of ustekinumab outside of clinical trials. OBJECTIVES: To assess the efficacy and safety of ustekinumab in patients with severe psoriasis attending 10 dermatology centres in the U.K. and Ireland. METHODS: A retrospective case-note review of 129 patients with psoriasis treated with ustekinumab. RESULTS: Baseline Psoriasis Area and Severity Index (PASI) was 22·9±10·1 (mean±SD). After 16weeks of treatment with ustekinumab PASI 75 (75% reduction in PASI) was observed in 63·0% (n=80/127) of patients, although four patients required concomitant therapy at the 16-week time point. Previous biologic use did show a small, non-significant trend towards treatment failure. A PASI 75 response was seen in 29·4% (n=5/17) of individuals weighing 90-100kg and treated with the standard 45mg ustekinumab dose compared with PASI 75 of 70·3%, 71·4%, 75·0% and 55·6% for weight groups <80, 80-90, 100-110 and >110kg, respectively (P=0·024). Ustekinumab therapy was well tolerated; serious adverse events were observed in 2·3% (n=3/129) of patients. CONCLUSIONS: Ustekinumab is a novel biologic agent for psoriasis. When used in everyday clinical practice it demonstrates high levels of short-term therapeutic efficacy with an acceptable short-term safety profile. |
| | |
Authors:
|
P M Laws; A M Downs; R Parslew; B Dever; C H Smith; J N Barker; B Moriarty; R Murphy; B Kirby; A D Burden; S McBride; A V Anstey; S O'Shea; N Ralph; C Buckley; C E M Griffiths; R B Warren |
Related Documents
:
|
21893626 - Long-term opioid therapy reconsidered. 21814776 - Intra-articular injection of hyaluronic acid (mw 1,500-2,000 kda; hyalone) in symptomat... 10820906 - Impact of helicobacter pylori eradication on the development of malt, gland atrophy and... 21952556 - Thalidomide in 42 patients with prurigo nodularis hyde. 16861096 - Long-term (120-week) antiviral efficacy and tolerability of fosamprenavir/ritonavir onc... 21701526 - Strabismus following retinal detachment repair: a comparison between scleral buckling a... |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The British journal of dermatology Volume: 166 ISSN: 1365-2133 ISO Abbreviation: Br. J. Dermatol. Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2012-01-03 Completed Date: 2012-03-16 Revised Date: 2013-05-31 |
Medline Journal Info:
|
Nlm Unique ID: 0004041 Medline TA: Br J Dermatol Country: England |
Other Details:
|
Languages: eng Pagination: 189-95 Citation Subset: IM |
Copyright Information:
|
© 2011 The Authors. BJD © 2011 British Association of Dermatologists. |
Affiliation:
|
Dermatological Sciences, Salford Royal Hospital, The University of Manchester, Manchester Academic Health Science Centre, Manchester M6 8HD, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antibodies, Monoclonal / therapeutic use* Biological Agents / therapeutic use* Body Mass Index Cost of Illness Dermatologic Agents / therapeutic use* Female Humans Male Middle Aged Psoriasis / drug therapy* Retrospective Studies Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Biological Agents; 0/Dermatologic Agents; FU77B4U5Z0/ustekinumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Description of the natural course and clinical manifestations of ichthyosis with confetti caused by ...
Next Document: Inhibition of benzalkonium chloride-induced skin inflammation in mice by an indol-1-ylpropan-2-one i...